Exploitation of transporters to develop novel antimicrobials against Gram-negative bacteria

我们需要新的抗生素类别，因为多重耐药(MDR)细菌正在威胁我们治疗传染病的能力。英国政府估计，如果没有新的抗生素，到2050年，传染病将给全球经济造成100万亿美元的损失。Discuva的创新(和专有)技术(Satin)是发现新抗生素的一个经过验证的平台；satin已经提供了具有新的作用机制的新的抗菌化合物，并在我们的牵头计划内计划于2017年进行临床试验，治疗耐多药淋病。该项目将使用这项英国发明的技术来提供改进的抗生素，这种抗生素对一些最具耐药性的致病细菌具有高度的活性，并且与传统抗生素相比，选择耐药性的可能性降低。这将解决与包括大肠杆菌在内的最具耐药性和最具生命威胁的细菌感染有关的临床失败的问题。最终，该项目有可能为患者、NHS(以及全球医疗保健系统)和抗菌素研究社区带来重大好处。

We need new classes of antibiotics because multi-drug resistant (MDR) bacteria are threatening our ability to treat infectious disease. The UK government estimates that without new antibiotics infectious disease will cost the global economy $100 trillion by 2050. Discuva’s innovative (and proprietary) technology (SATIN) is a proven platform for the discovery of new antibiotics; SATIN has already delivered new antibacterial compounds with novel mechanisms-of-action and within our lead programme clinical trials are planned in 2017 for the treatment of MDR gonorrhoea. This project will use this UK invented technology to deliver improved antibiotics which are both highly active against some of the most resistant bacteria causing disease and have a reduced likelihood of selecting resistance compared to conventional antibiotics. This will address the issue of clinical failure associated with the most resistant and life-threatening bacterial infections including E. coli. Ultimately, this project has potential for significant benefits to patients, the NHS (and health care systems globally), and the antibiotc research community.